Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping review

Ruiz-García, A; Pallarés-Carratalá, V; Serrano-Cumplido, A; Escobar-Cervantes, C; Barquilla-García, A; Divisón-Garrote, J. A; Turégano-Yedro, M; Prieto-Díaz, M. A; Cinza-Sanjurjo, S; Alonso-Moreno, F. J; Beato-Fernández, P.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 48(4): 275-292, mayo - jun. 2022. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-205239

Documentos relacionados

  1. Is There Still a Role for Aspirin in Primary Prevention in Women in 2020?
  2. Association Between <i>CYP2B6</i> Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack.
  3. First-trimester preterm preeclampsia prediction model for prevention with low-dose aspirin.
  4. Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention.
  5. Aspirin for primary prevention of cardiovascular disease: is it time to move on?
  6. Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention.
  7. Feasibility of Universal Screening for Preeclampsia Risk and Aspirin Recommendation in the Ultrasound Unit.
  8. Secondary Prevention with Antithrombotic Therapies in Stable Ischemic Heart Disease Patients: a Review.
  9. Uso de aspirina en prevención primaria cardiovascular: es tiempo de cambiar el paradigma
  10. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.